Kelzy

Dienogest, the active ingredient in Kelzy, is a combined estrogen‑progestogen oral contraceptive presented as an oral tablet for systemic use. It is indicated for preventing pregnancy in women of reproductive age and may also help regulate menstrual cycles.

GNH USA supplies Kelzy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. Kelzy is manufactured under EU Good Manufacturing Practice guidelines and is distributed to meet the needs of diverse patient populations.

Kelzy, a combined estrogen‑progestogen oral contraceptive, is used in the hormonal regulation pathway to prevent unintended pregnancy.

- Contraception: prevents pregnancy by inhibiting ovulation and altering cervical mucus. - Menstrual cycle regulation: provides more predictable bleeding patterns and reduces menstrual‑related discomfort. - Moderate acne treatment: helps improve acne lesions associated with hormonal fluctuations.

Oral administration of Kelzy may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild stomach upset, often transient. - Breast tenderness: discomfort or swelling of the breasts. - Headache: mild to moderate intensity. - Spotting or breakthrough bleeding: irregular light bleeding between periods. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Severe hypertension: sudden increase in blood pressure. - Liver dysfunction: jaundice or abnormal liver enzymes. - Allergic reaction: rash, swelling, or anaphylaxis. - Visual disturbances: blurred vision or loss of sight.

Before prescribing Kelzy, healthcare professionals should evaluate patient risk factors and provide appropriate counseling. - Cardiovascular assessment: review history of thrombosis, hypertension, or smoking. - Liver function: avoid use in patients with severe hepatic impairment. - Smoking restriction: advise women under 35 not to smoke more than 15 cigarettes per day. - Missed dose guidance: instruct on actions if a tablet is omitted to maintain efficacy. - Drug interaction review: assess concomitant use of enzyme‑inducing agents. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Kelzy can interact with other medicines that affect hormone metabolism or coagulation pathways.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may reduce anticoagulant effect and increase clot risk. - Hepatic enzyme inducers (e.g., rifampin, carbamazepine): can lower contraceptive hormone levels, reducing efficacy. - Certain antiretrovirals (e.g., protease inhibitors): may alter hormone concentrations leading to failure.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., tetracycline, fluoroquinolones): may slightly decrease contraceptive effectiveness. - St. John’s wort: herbal inducer that can reduce hormone levels.